Flumazenil reverses the drowsiness and sedation that occurs when patients take a class of psychoactive drugs called benzodiazepines. The estimated U.S. market size for the drug is about $4 million.
Claris currently has 16 drug approvals, with 23 pending. The company expects more market approvals before the end of the year.
More articles on supply chain:
FDA fast tracks experimental drug to treat Parkinson’s
Roche’s Zika test earns FDA emergency use authorization
Mylan to introduce generic EpiPen at half the price
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
